Endothelins in inflammatory neurological diseases

• Published in: Pharmacology & therapeutics (Oxford) Vol. 194; pp. 145 - 160
• Main Authors: D'Orléans-Juste, Pedro, Akide Ndunge, Oscar B., Desbiens, Louisane, Tanowitz, Herbert B., Desruisseaux, Mahalia S.
• Format: Journal Article
• Language: English
• Published: England Elsevier Inc 01.02.2019
• Subjects: Animals; Blood-brain barrier (BBB); Central nervous system; Cerebral blood flow (CBF); Chymase; Cytokines; Endothelin subtype A receptor (ETA); Endothelin subtype B receptor (ETB); Endothelin-1 (ET-1); Endothelins - metabolism; Humans; Inflammation - metabolism; Mast cells; Nervous System Diseases - metabolism; APP; CXCL; NO; BBB; CBF; Central nervous system; Blood-brain barrier (BBB); CNS; ICAM-1; HSV-2; SLE; HAND; Aβ; CNSV; HSV-1; KSHV; DENV; HHV; AD; Cytokines; GCA; Endothelin subtype A receptor (ETA); ECE; MS; EAE; KS; CM; Cerebral blood flow (CBF); CCL; CMV; Endothelin-1 (ET-1); Chymase; ET; ETB; VCAM-1; ET-1; ETA; HIV; Endothelin subtype B receptor (ETB); NEP; Mast cells; VSMC; Endothelin subtype B receptor (ET(B)); Endothelin subtype A receptor (ET(A))

Endothelins were discovered more than thirty years ago as potent vasoactive compounds. Beyond their well-documented cardiovascular properties, however, the contributions of the endothelin pathway have been demonstrated in several neuroinflammatory processes and the peptides have been reported as cli...